Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
G7 should act as stabilizer and reformer to reshape international order, urges T7 report
-
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
-
Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US
-
Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025
-
Ocean Power Technologies Awarded Contract to Provide Multiple Unmanned Surface Vehicles for International Defense Customer
-
Navigator Gas Announces Signing of $300 Million Senior Secured Term Loan and Revolving Credit Facility
-
Aspo to publish its Interim Report for January-March 2025 on May 12, 2025
-
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
-
MARA Announces Bitcoin Production and Mining Operation Updates for April 2025
-
Early Warning News Release Regarding the Securities of Euromax Resources Ltd.
-
Kornit Digital and Gooten Expand Access to Kornit’s Global Fulfillment Network for On-Demand Production
-
4DMT to Participate in Upcoming Investor Conferences
-
Ryman Hospitality Properties, Inc. Provides Updated Investor Presentation
-
Greenridge Exploration Announces 2025 Exploration Plans for the Blackbird Project in Northern Saskatchewan
-
SHARC Energy Announces Board of Director Changes
-
Enphase Energy to Hold 2025 Annual Meeting of Stockholders on May 14, 2025
-
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
-
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
-
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
-
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
-
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
-
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
-
Aemetis to Review First Quarter 2025 Financial Results on May 8, 2025
-
Sell Fast Chicagoland: Home Cash Buyers in Chicago Celebrate 20 Years of Delivering Swift Property Solutions
-
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
-
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
-
BigCommerce Taps Technology Industry Veteran with Strong Record of Innovation as Chief Product Officer
-
Cerence AI and Code Factory Collaborate to Bring Voice-Powered Interaction to Self-Service Kiosks
-
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
-
Valueex (VUEE) Exchange Opens IEO Window, Leading New Opportunities in Global Blockchain Investment
-
Voreifarem Partners with SwfcNrho Exchange to Create a Global New Paradigm for Medical Data Valuation
-
DeFi Dev Corp. Advances Solana Treasury Strategy with Validator Business Acquisition
-
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
-
Nature’s Sunshine Appoints Heidi Wissmiller as Chairman of the Board
-
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
-
HomesToLife Ltd Announces Acquisition of HTL Marketing Pte Ltd, with 2024 Sales of US$330 Million
-
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
-
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
-
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
-
Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia
-
22nd Century Group to Announce First Quarter 2025 Results on May 13, 2025
-
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
-
Study Shows Large Improvements in Long COVID Symptoms and Return to Work
-
MediWound to Report First Quarter 2025 Financial Results
-
Alpha Modus Reaches Settlement Agreement with Kroger in Patent Litigation
-
LPL Financial Welcomes Northern Advisory Group
-
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress
-
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025
-
Hydreight Technologies Appoints Dr. Roebuck As a Director of the Company
